Literature DB >> 7967223

Binding characteristics of a histamine H3-receptor antagonist, [3H]S-methylthioperamide: comparison with [3H](R)alpha-methylhistamine binding to rat tissues.

K Yanai1, J H Ryu, N Sakai, T Takahashi, R Iwata, T Ido, K Murakami, T Watanabe.   

Abstract

The release and synthesis of neuronal histamine are regulated by histaminergic autoreceptors named as histamine H3 receptors. The development of radiolabeled histamine H3 antagonists is needed to characterize the binding of antagonists to these receptors. Here we describe the binding characteristics of a new histamine H3-receptor antagonist, [3H]S-methylthioperamide (SMT), to rat tissues, and compare its binding with that of [3H](R)alpha-methylhistamine ((R)alpha MH), a selective histamine H3-receptor agonist. The binding of [3H]SMT to the membranes of rat forebrain was found to be stereoselective, saturable, reversible and temperature-dependent. Saturation binding experiments indicated a single class of high affinity sites for [3H]SMT in forebrain membranes (KD = 2.1 nM, Bmax = 24.3 pmol/g of tissue at 4 degrees C). The Bmax was approximately 3 times that of [3H](R)alpha MH binding to rat forebrain membranes (KD = 2.5 nM, Bmax = 7.3 pmol/g of tissue at 25 degrees C). Autoradiographic images of [3H]SMT binding in the brain were essentially the same as those of [3H](R)alpha MH. [3H]SMT also bound appreciably to peripheral tissues (the liver, adrenal, stomach, ileum, kidney, lung and bladder), whereas the [3H](R)alpha MH bindings to these peripheral tissues were negligible. These results indicate that [3H]SMT binds to H3 receptors primarily in the central nervous system, and that it also has high affinity toward non-H3 receptors, probably hemoproteins, in peripheral tissues.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7967223     DOI: 10.1254/jjp.65.107

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  8 in total

1.  Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.

Authors:  David G Witte; Betty Bei Yao; Thomas R Miller; Tracy L Carr; Steven Cassar; Rahul Sharma; Ramin Faghih; Bruce W Surber; Timothy A Esbenshade; Arthur A Hancock; Kathleen M Krueger
Journal:  Br J Pharmacol       Date:  2006-05-22       Impact factor: 8.739

Review 2.  An update on histamine H3 receptors and gastrointestinal functions.

Authors:  G Bertaccini; G Coruzzi
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

3.  Effects of iodoproxyfan, a potent and selective histamine H3 receptor antagonist, on alpha 2 and 5-HT3 receptors.

Authors:  E Schlicker; H Pertz; H Bitschnau; K Purand; M Kathmann; S Elz; W Schunack
Journal:  Inflamm Res       Date:  1995-07       Impact factor: 4.575

4.  The effect of dopamine D1 receptor stimulation on the up-regulation of histamine H3-receptors following destruction of the ascending dopaminergic neurones.

Authors:  J H Ryu; K Yanai; X L Zhao; T Watanabe
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

5.  Characterization of the binding of [3H]-clobenpropit to histamine H3-receptors in guinea-pig cerebral cortex membranes.

Authors:  E A Harper; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

6.  [3H]-thioperamide as a radioligand for the histamine H3 receptor in rat cerebral cortex.

Authors:  A Alves-Rodrigues; R Leurs; T S Wu; G D Prell; C Foged; H Timmerman
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 7.  International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.

Authors:  Pertti Panula; Paul L Chazot; Marlon Cowart; Ralf Gutzmer; Rob Leurs; Wai L S Liu; Holger Stark; Robin L Thurmond; Helmut L Haas
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

8.  Pharmacological effects of carcinine on histaminergic neurons in the brain.

Authors:  Zhong Chen; Eiko Sakurai; Weiwei Hu; Chunlei Jin; Yoshinobu Kiso; Motohisa Kato; Takehiko Watanabe; Erqing Wei; Kazuhiko Yanai
Journal:  Br J Pharmacol       Date:  2004-10-04       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.